Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.33 |
| ▸ | SMPD1 | P17405 | 3/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.31 |
| ▸ | FDPS | P14324 | 3/20 | 0.31 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.31 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8644486 | 0.89 | TSHR (0.42) | TSHRLMNADNM1OPRM1THRB | |
| SCHEMBL2601778 | 0.89 | TSHR (0.42) | TSHRLMNADNM1OPRM1THRB | |
| SCHEMBL12939814 | 0.89 | TSHR (0.42) | TSHRLMNADNM1OPRM1THRB | |
| SCHEMBL29525101 | 0.87 | TSHR (0.40) | TSHRLMNADNM1OPRM1THRB | |
| SCHEMBL1960012 | 0.87 | TSHR (0.43) | TSHRLMNADNM1OPRM1THRB | |
| Hydrochloric Acid SCHEMBL29189739 | 0.85 | TSHR (0.42) | TSHRLMNADNM1OPRM1THRB | |
| Hydrochloric Acid SCHEMBL5480968 | 0.85 | TSHR (0.42) | TSHRLMNADNM1OPRM1THRB | |
| SCHEMBL28132173 | 0.82 | TSHR (0.47) | TSHRLMNADNM1SMPD1OPRM1 | |
| SCHEMBL28066893 | 0.82 | TSHR (0.47) | TSHRLMNADNM1SMPD1OPRM1 | |
| SCHEMBL7158134 | 0.81 | TSHR (0.42) | TSHRLMNADNM1OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120094999-A1 | EGFR INHIBITORS AND METHODS OF TREATING DISORDERS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2012-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120094999-A1 | EGFR INHIBITORS AND METHODS OF TREATING DISORDERS | EGFR, ERBB2, ERBB4 | TSHR 269/4885LMNA 4831/4885DNM1 1913/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.